[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
June 8, 2011

A Strategic Approach to Therapeutic Cancer Vaccines in the 21st Century

Author Affiliations

Author Affiliations: Child Health Evaluation and Research Unit, Division of General Pediatrics, Division of General Medicine and the Gerald R. Ford School of Public Policy (Dr Davis); and University of Michigan Medical School (Mr Dayoub), University of Michigan, Ann Arbor.

JAMA. 2011;305(22):2343-2344. doi:10.1001/jama.2011.814

Prophylactic vaccines have forever reduced the burden of disease in the United States and around the world.1 One of the critical keys to success for prophylactic vaccines was that scientists set their sights on high-burden infectious diseases—frequently with high incidence, and often with high rates of mortality and morbidity and minimally effective therapeutic options at the time vaccines were developed.

First Page Preview View Large
First page PDF preview
First page PDF preview
×